Related Experiment Video
Updated: Jul 24, 2025
Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
Published on: September 25, 2011
Genomic landscape and expression profile of consensus molecular subtype four of colorectal cancer
Yujie Lu1, Dingyi Gu1, Chenyi Zhao1
1Department of Oncology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, China.
Background:
Compared to other subtypes, the CMS4 subtype is associated with lacking of effective treatments and poorer survival rates.
Methods:
A total of 24 patients with CRC were included in this study. DNA and RNA sequencing were performed to acquire somatic mutations and gene expression, respectively. MATH was used to quantify intratumoral heterogeneity. PPI and survival analyses were performed to identify hub DEGs. Reactome and KEGG analyses were performed to analyze the pathways of mutated or DEGs. Single-sample gene set enrichment analysis and Xcell were used to categorize the infiltration of immune cells.
Results:
The CMS4 patients had a poorer PFS than CMS2/3. CTNNB1 and CCNE1 were common mutated genes in the CMS4 subtype, which were enriched in Wnt and cell cycle signaling pathways, respectively. The MATH score of CMS4 subtype was lower. SLC17A6 was a hub DEG. M2 macrophages were more infiltrated in the tumor microenvironment of CMS4 subtype. The CMS4 subtype tended to have an immunosuppressive microenvironment.
Conclusion:
This study suggested new perspectives for exploring therapeutic strategies for the CMS4 subtype CRC.
Insights
The CMS4 subtype of colorectal cancer (CRC) shows poorer survival and limited treatment options. This study identified key mutations and immune cell profiles in CMS4 CRC, offering new therapeutic targets.
Area of Science:
- Oncology
- Genomics
- Immunology
Background:
- The CMS4 subtype of colorectal cancer (CRC) is characterized by poor prognosis and a lack of effective therapies.
- Identifying molecular and immunological features of CMS4 CRC is crucial for developing targeted treatments.
Purpose of the Study:
- To investigate the genomic landscape, gene expression profiles, and tumor microenvironment of the CMS4 CRC subtype.
- To identify potential therapeutic targets and biomarkers for CMS4 CRC.
Main Methods:
- Whole exome sequencing and RNA sequencing were performed on 24 CRC patients.
- Intratumoral heterogeneity was quantified using the Mutational Allelic Burden (MATH) score.
- Pathway analysis, gene enrichment analysis, and immune cell infiltration analysis were conducted.
Main Results:
- CMS4 patients exhibited worse progression-free survival (PFS) compared to CMS2/3 subtypes.
- Commonly mutated genes in CMS4 CRC included CTNNB1 (Wnt pathway) and CCNE1 (cell cycle pathway).
- CMS4 tumors showed lower MATH scores, enrichment of M2 macrophages, and an immunosuppressive tumor microenvironment.
Conclusions:
- The CMS4 subtype of CRC presents distinct genomic alterations and a unique immune microenvironment.
- These findings provide novel insights for developing targeted therapeutic strategies for CMS4 CRC patients.
